Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 1,212,606 shares, an increase of 70.6% from the October 13th total of 710,794 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily volume of 2,204,410 shares, the days-to-cover ratio is presently 0.6 days.
Imprimis Pharmaceuticals (IMMY) opened at $1.58 on Monday. Imprimis Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.69. The company has a current ratio of 1.88, a quick ratio of 1.55 and a debt-to-equity ratio of 1.68.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last issued its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.29. The company had revenue of $6.86 million for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 242.66% and a negative net margin of 57.07%.
Hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in shares of Imprimis Pharmaceuticals by 60.7% during the second quarter. Bank of New York Mellon Corp now owns 35,606 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 13,455 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Imprimis Pharmaceuticals by 78.2% during the second quarter. Vanguard Group Inc. now owns 451,226 shares of the specialty pharmaceutical company’s stock worth $1,444,000 after purchasing an additional 198,068 shares during the last quarter. Finally, KCG Holdings Inc. purchased a new position in shares of Imprimis Pharmaceuticals during the first quarter worth about $130,000. 17.86% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://ledgergazette.com/2017/11/13/short-interest-in-imprimis-pharmaceuticals-inc-immy-grows-by-70-6.html.
About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.